Roquefort Therapeutics (LON:ROQ) Shares Down 14.9% – Here’s Why

Roquefort Therapeutics plc (LON:ROQ) dropped 14.9% during trading on Tuesday . The stock traded as low as GBX 3.18 ($0.04) and last traded at GBX 3.32 ($0.04). Approximately 1,854,913 shares changed hands during mid-day trading, an increase of 41% from the average daily volume of 1,314,913 shares. The stock had previously closed at GBX 3.90 ($0.05).

Roquefort Therapeutics Stock Performance

The stock’s fifty day simple moving average is GBX 4.04 and its 200-day simple moving average is GBX 4.02. The company has a quick ratio of 3.07, a current ratio of 0.79 and a debt-to-equity ratio of 12.37. The company has a market capitalization of £3.36 million, a PE ratio of -260.00 and a beta of 0.05.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.